Table 1 Patient characteristics.

From: Predictive value of subharmonic-aided pressure estimation for diagnosing clinically significant portal hypertension

Variable

All patients (n = 62)

Patients without CSPH (n = 38)

Patients with CSPH (n = 24)

p value

HVPG (mmHg)

7.5 (5, 12)

5 (4, 7)

14 (11, 16)

< 0.01

Age (years)

75 (68, 80)

75 (69, 82)

73.5 (68, 76)

0.25

Male sex (%)

44 (70)

28 (74)

16 (67)

0.58

Body mass index (kg/m2)

24.7 (22.4, 27.5)

24.8 (22.0, 27.1)

24.5 (22.5, 28.8)

0.39

Etiology;

31/15/13/3

22/8/7/1

9/7/6/2

0.53

Virus/MASLD/ALD/Other diseases

High-risk varices (%)

8 (13)

2 (5)

6 (25)

0.04

MELD score

3 (1, 7)

2.5 (1, 6)

4.5 (2.5, 9.5)

0.04

MELD-Na score

3.5 (0, 6)

1.5 (− 1, 6)

4.5 (1.5, 11.5)

0.03

Child–Pugh score; 5/6/7/8/9/10

41/9/6/4/2/0

30/5/2/1/0/0

11/4/4/3/2/0

0.03

ALBI score

− 2.63 (− 2.93, − 2.14)

− 2.77 (− 2.95, − 2.60)

− 2.26 (− 2.61, − 1.85)

< 0.01

FIB-4 index

4.33 (2.68, 5.71)

3.19 (1.96, 4.34)

5.54 (4.71, 8.55)

< 0.01

Laboratory parameter

Albumin (g/dL)

4.0 (3.5, 4.3)

4.2 (3.9, 4.4)

3.6 (3.4, 3.9)

< 0.01

Total bilirubin (mg/dL)

1.0 (0.7, 1.2)

0.8 (0.6, 1.0)

1.1 (0.8, 1.5)

0.02

ALT (U/L)

22 (16, 35)

20 (15, 28)

33 (20, 47)

0.01

Platelet count (G/L)

13.1 (9.4, 18.9)

15.6 (11.5, 20.6)

10.6 (8.3, 13.8)

< 0.01

Prothrombin time (%)

85.7 (68.7, 100.1)

90.4 (76, 102.4)

80 (65, 92)

0.02

Ammonia (μg/dL)

47 (35, 72)

42 (33, 65)

56 (39, 96)

0.10

M2BPGi (COI)

2.04 (1.05, 4.04)

1.25 (0.92, 2.05)

4.08 (2.78, 7.37)

< 0.01

Hyaluronic acid (ng/mL)

134 (82, 321)

99 (53, 150)

308 (141, 481)

< 0.01

Collagen type IV (ng/mL)

5.8 (4.1, 8.9)

4.6 (4.0, 6.3)

8.9 (6.8, 12.0)

< 0.01

LSM by VCTE (kPa)

13.9 (7.2, 21.4)

9.7 (6.1, 13.8)

25.7 (18.6, 37.8)

< 0.01

SSM by VCTE (kPa)

30.3 (20.7, 52.7)

21.1 (17.4, 30.4)

52.3 (31.8, 67.9)

< 0.01

SHAPE gradient (dB)

− 3.7 (− 5.5, − 1.8)

− 5.1 (− 6.4, − 3.9)

− 1.6 (− 2.3, 0.2)

< 0.01

  1. Quantitative variables are presented as the median and interquartile range.
  2. ALD alcoholic liver disease; ALT aspartate aminotransferase; ALBI albumin-bilirubin; FIB-4 fibrosis-4; MASLD metabolic dysfunction-associated liver disease; MELD model for end-stage liver disease; M2BPGi Mac-2 binding protein glycosylation isomer; HVPG hepatic venous pressure gradient; LSM liver stiffness measurement; SHAPE subharmonic-aided pressure estimation; SSM spleen stiffness measurement; VCTE vibration-controlled transient elastography.
Back to article page